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Abstract 
Paracetamol (Acetaminophen) is the most commonly used drug in the world, with a long 
record of use in acute and chronic pain. In recent years the benefits of paracetamol use in 
chronic conditions has been questioned, notably in the areas of osteoarthritis and lower 
back pain. Over the same period, concerns over the long-term adverse effects of 
paracetamol use have increased, initially in the field of hypertension, but more recently in 
other areas also.  
 
The evidence base for adverse effects of chronic paracetamol use consists of many cohort 
and observational studies, with few randomised controlled trials that in many cases 
contradict each other, so these studies must be interpreted with caution. Nevertheless, 
there are some areas where the evidence for harm is more robust, and if a clinician is 
starting paracetamol with the expectation of chronic use it might be advisable to discuss 
these side effects with patients first. In particular, an increased risk of GI bleeding and a 
small (~4mmHg) increase in systolic BP are adverse effects for which the evidence is 
particularly strong, and which show a degree of dose dependence. As our estimation of the 
benefits decreases, an accurate assessment of the harms is ever more important. This 
review summarises the current evidence on the harms associated with chronic paracetamol 
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Abstract Word Count: 229 
 
Introduction 
Paracetamol (acetaminophen) was first synthesised in 1878 [1], from its precursor 
phenacetin. Its use was not widespread initially, due to early reports of a link to 
methaemoglobinaemia [2, 3]. After this association was discredited, it was marketed in the 
1950s as a safer alternative to phenacetin, which by then had been found to be nephrotoxic 
and potentially carcinogenic [4]. In the early 1980s, paracetamol overtook aspirin as the 
most widely used over-the-counter analgesic in the UK [5]. It is now the most commonly 
used analgesic in the world [6], and the first step of the World Health Organisation (WHO) 
analgesic ladder for treatment of cancer pain [7]. 
 
Paracetamol is currently marketed as an analgesic and antipyretic, to be used for no more 
than three days without consulting a doctor [8]. However, due in part to its inclusion in the 
WHO analgesic ladder, as well as decades of clinical experience, it is also prescribed in 
chronic conditions such as osteoarthritis and lower back pain. Recently, meta-analyses of 
the randomised controlled trials covering these conditions have shown the effect sizes to be 
modest, though still statistically significant, compared with placebo (averaging a 4-5% 
reduction in pain) [9-12]. Despite this, paracetamol continues to be recommended as first-
line treatment in UK guidelines [13], and attempts to remove paracetamol as a 
recommendation from the UK’s National Institute for Health and Care Excellence (NICE) 
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guidance on osteoarthritis raised considerable concerns amongst medicines regulators and 
various specialist societies [14], particularly as this would leave opioids as the major 
alternative. Given the current opioid addiction epidemic ongoing in several US states [15], 
and a desire not to repeat this in the UK [16, 17], the introduction of opioids earlier in the 
pain management pathway is unlikely to be viewed favourably.  
 
Paracetamol has less of an analgesic effect in chronic use than previously thought; there 
needs to be greater emphasis on accurately determining the harms of long-term use at 
therapeutic doses. This helps clinicians balance harms against likely benefits for individual 
patients and allows regulators to make recommendations on its availability in over-the-
counter preparations. The acute effects of paracetamol ingestion in overdose are well-
known [18]. Harms with long-term therapeutic use are less clear. Concerns have been raised 
over the effects on the cardiovascular, respiratory, renal, gastrointestinal and central 
nervous systems, as well as potential effects in the offspring of pregnant women ingesting 
paracetamol.  
 
This review summarises our understanding of the evidence on adverse effects of 
paracetamol in long-term therapeutic use, informs clinicians of the risks and provides a 
clearer picture of the underpinning evidence-base. This will, in turn, allow clinicians to 
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Mechanism of action 
The mechanism of action of paracetamol is not completely understood, but likely involves 
cyclo-oxygenase-2 (COX-2) inhibition. Traditional nonsteroidal anti-inflammatory drugs 
(NSAIDs) inhibit cyclooxygenase (COX) enzymes, preventing the metabolism of arachidonic 
acid to prostaglandin (PG) G2. COX enzymes also have a separate peroxidase function, and 
metabolise PG-G2 to PG-H2, which is in turn converted to several different prostaglandins by 
local tissues according to their individual needs [2, 19, 20]. Unlike the closely-related 
NSAIDs, paracetamol interferes with the peroxidase activity of COX isoenzymes, 
predominantly COX-2, particularly when the cellular environment is low in arachidonic acid 
and peroxides [2, 19, 20]. This explains paracetamol’s apparent ‘central’ effect in earlier 
studies (as COX-2 is constitutively expressed in neural tissue) [19, 21], and why it appears to 
be ineffective in inflamed tissues (where peroxide and arachidonic acid are abundant), seen 
in conditions such as rheumatoid arthritis. A proposed COX-3 isoenzyme (an exon splice 
variant of COX-1 seen in insects and rodents) has not been found in humans, and further 
studies suggest that paracetamol has no clinically significant effects on the COX-1 exon 
splice variants found so far in humans [19, 21]. Other possible mechanisms of action include 
the inhibition of anandamide reuptake (and subsequent cannabinoid receptor CB1 
stimulation) by paracetamol metabolite N-arachidonoylphenolamine (AM404), which is 
produced by the conjugation of arachidonic acid and deacetylated paracetamol [22], and 
direct activation of the capsaicin receptor TRPV1 by AM404 [23]. TRPA1 activation by 
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Paracetamol is mostly metabolised by the formation of conjugates (with glucuronide and 
sulphate), and subsequently excreted in urine. In therapeutic dosing, around 10% of 
paracetamol is metabolised by cytochrome P450 enzymes to form n-acetyl-p-
benzylquinoneimine (NAPQI), which is subsequently conjugated with intracellular 
glutathione, and ultimately excreted as cysteine and mercaptopuric acid conjugates. Less 
than 5% is excreted unchanged [26].  
 
Search Strategy 
We conducted a literature search of PubMed, searching the years 1980 to 2016. An initial 
Pubmed review of “paracetamol [Title] OR acetaminophen [Title]” with “side effects OR 
adverse effects” revealed several key interest areas, which were subsequently searched for 
specifically as follows: we combined “paracetamol [Title] OR acetaminophen [Title]” with: 
“hypertension OR blood pressure”; “myocardial infarction OR cardiac OR cardiovascular”; 
“stroke OR CVA OR cerebrovascular accident”; “liver OR hepatic OR transaminase OR 
aminotransferase”; “gastrointestinal OR bleeding OR anaemia”; “renal OR kidney OR CKD 
OR chronic kidney disease”; “respiratory OR asthma OR chest”; “reproductive OR maternal 
OR ADHD OR attention deficit”. Papers were selected with the following criteria: 1) human 
subjects; and 2) meta-analyses, reviews, randomised controlled trials, prospective studies 
and cohort studies. English language was not included as a filter but would not have 
excluded any papers from review. Titles and abstracts were then reviewed, and relevant 
articles reviewed in full. Key papers identified in references were also reviewed by the 
authors, where considered relevant. See Figure 1 for our search strategy.  
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Key protein targets and ligands in this article are hyperlinked to corresponding entries in 
http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS 
Guide to PHARMACOLOGY [27], and are permanently archived in the Concise Guide to 
PHARMACOLOGY 2017/18 [28]. 
 
Cardiovascular  
Studies examining the effect of paracetamol on the incidence of cardiovascular disease are 
relatively sparse when compared to those on NSAIDs [29]. Early studies focused on 
hypertension (which we have reviewed previously [30]), due to the known association of 
NSAIDs with hypertension, and the similar mechanism of action of paracetamol [31]. One 
such study was a placebo-controlled crossover study of 20 treated hypertensive patients, 
where a 4 mmHg rise in blood pressure (BP) was found when paracetamol was administered 
[32]. Given that a 2mmHg rise in systolic BP is associated with a 7% increase in risk of 
ischaemic heart disease and a 10% increased risk of stroke [33], this apparently small 
increase in BP could have serious population-based consequences.  
 
However, both observational and interventional studies examining the effect of 
paracetamol on hypertension have produced conflicting results [30]. To date, most [34-36], 
but not all [37, 38], observational studies suggest that long-term paracetamol use increases 
the risk of developing hypertension. The Nurses' Health Study II, which included 80,020 
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participants, found that regular NSAID or paracetamol use was associated with an increased 
risk of developing hypertension [35]: the relative risk of developing hypertension on NSAIDS 
was 1.86 (95% confidence interval [CI] 1.51-2.28) and on paracetamol was 2.00 (95% CI 
1.52-2.62).  It also seems that there is some evidence for a dose-response relationship 
between daily paracetamol dosage and risk of incident hypertension. This was observed not 
only in the Nurses Health Studies I and II [39], but also by Roberts et al. for overall 
cardiovascular risk in their systematic review of paracetamol-related adverse effects [6]. 
 
In contrast, a retrospective observational study by Dawson et al., with propensity matching, 
found no impact of paracetamol on BP in a cohort of 2,754 participants with treated 
hypertension [38]. Although observational studies may find an association between 
paracetamol use and hypertension, underlying confounders (such as chronic inflammatory 
conditions) need to be considered. Unfortunately, to date, interventional studies examining 
the impact of paracetamol on BP have been limited by study design and small sample size. 
One recent study, by Sudano et al., randomised 33 patients with established coronary artery 
disease to paracetamol 1g three times per day or placebo in a double-blinded crossover 
study [40]. Two weeks of treatment with paracetamol significantly increased mean systolic 
ambulatory BP (from 122± 12 to 125 ± 12 mmHg, p=0.02) and diastolic ambulatory BP (from 
73 ± 7 to 75 ± 8 mmHg, p=0.02). Though this difference is unlikely to significantly affect an 
individual patient’s cardiovascular outcomes, it may explain the finding that self-reported 
frequent paracetamol use in women is associated with an increase in cardiovascular events 
similar to that seen with frequent NSAID use [41]. Fulton et al. showed no increased risk of 
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myocardial infarction or stroke in a hypertensive cohort of 4,000 subjects, and no change in 
BP, which suggests that any increase in risk may be driven by BP alone [42].  Further 
research in this area is clearly required, and there is currently a suitably-powered double-
blind, placebo-controlled, crossover trial from our centre examining the effects of 2 weeks 
of paracetamol use on BP in hypertensive patients 
(https://clinicaltrials.gov/ct2/show/NCT01997112), that should report soon. 
 
Respiratory 
After aspirin was recognised to cause the rare but serious complication of Reye’s syndrome, 
its use was banned in under-12s, [43, 44]. As aspirin use as an antipyretic waned in 
developed countries and paracetamol use became more common [45], concerns over 
paracetamol’s association with asthma were raised [46]. Observational and cross-sectional 
studies demonstrated a connection between paracetamol use and asthma diagnoses or 
exacerbations [47-54]. However, as for BP, almost all of these studies suffer from 
confounding by indication: recurrent symptomatic respiratory infections and febrile illnesses 
are more common in asthmatic patients and contribute to the onset of asthma in childhood 
[55-57]. In some studies an increased risk/odds for developing asthma with increasing 
paracetamol use becomes nonsignificant when adjusted for recurrent respiratory tract 
infection [58-60], though this is not universal [53]. Meta-analyses of these observational 
studies tend to show only a small effect (e.g. odds ratio [OR] 1.15 for use in infancy), and 
suffer from considerable heterogeneity [47, 55].  
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A link between paracetamol use and asthma is biologically plausible. Paracetamol 
metabolism involves the antioxidant glutathione, which is depleted when large doses of 
paracetamol are taken. There are papers describing glutathione depletion at therapeutic 
doses of paracetamol [61, 62] and increased oxidative stress could contribute towards 
either the development of asthma or inflammatory exacerbations in asthmatics [63-67]. 
Glutathione depletion may also change T helper (Th) physiology towards a Th2 phenotype, 
which is associated with atopic disease [49]. Paracetamol may also cause an imbalance in 
lipooxygenase activity, brought about by COX inhibition, resulting in increased leukotriene 
and decreased prostaglandin E2 production [63, 64, 68]. This latter mechanism has support 
from studies done in patients with aspirin-associated asthma, where decreases in Forced 
Expiratory Volume in 1 second (FEV1) following paracetamol administration were observed 
[69]. In one such study, 34% of aspirin-sensitive participants showed cross-reactivity to 
paracetamol [70], and in patients with aspirin-associated asthma it is recommended to use 
the lowest effective dose of paracetamol for analgesia [71, 72]. It should be noted that a 
later double-blind, randomised controlled trial (RCT) in non-aspirin-sensitive subjects (n=85) 
taking paracetamol 1g twice daily or placebo for 12 weeks showed no differences in 
bronchial hyperresponsiveness [73].  
 
A few researchers have attempted to study the effects of paracetamol on asthmatic patients 
(adult and paediatric) in RCTs. Ioannides et al. randomised adults with mild to moderate 
asthma to placebo or paracetamol 4g/d for 12 weeks, then submitted them to a 
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methacholine challenge test. Airway hyper-responsiveness was similar in both groups 
(amount of methacholine required to reduce FEV1 by 20%, paracetamol group – placebo 
was -0.48 mg/ml, 95% CI -1.28 – 0.32) but this study was notably underpowered (n=94; 
recommended sample size 650) [73]. More recently, Sheehan et al. conducted an RCT where 
they randomised children aged 0.5 – 5 years to receive either paracetamol or ibuprofen for 
analgesia/antipyresis over the following 48 weeks. Participants received a mean of 5.5 doses 
(range 1-15), with no between-group differences. Relative risk for asthma exacerbations was 
similar between the two groups, and there were no significant differences in secondary 
outcomes (asthma-controlled days, unscheduled care, use of rescue medication), indicating 
that, at least in mild to moderately asthmatic children, paracetamol was as safe to use as 
ibuprofen [74].  
Overall, there is evidence of a weak association of paracetamol use with asthma, but 
causation cannot be established. RCTs are limited, but seem to provide reassurance that 
paracetamol is safe to use in patients with established asthma [73-75].  
 
Gastrointestinal  
The acute effects on the liver of paracetamol in overdose have been well-documented [76-
78]. However, the effect of chronic therapeutic-dose paracetamol use on the liver and 
gastrointestinal (GI) system in general is less clear. Concerns are generally focused around 
GI blood loss and chronic hepatotoxicity.  
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Gastrointestinal bleeding 
Paracetamol has long been considered the ‘safe’ analgesic alternative to NSAIDs in patients 
prone to GI bleeding. Indeed, in studies of the analgesic effects of NSAIDS it is commonly 
used as a comparator, due to the ethical issues of withholding analgesia [79-81]. There is 
some evidence to support the safety of paracetamol. Examining adverse events reported in 
the Spanish drug monitoring system, Carvajal et al. found paracetamol use was associated 
with nausea (3.3% of all reported adverse events) and dyspepsia (4.2%), but not GI bleeding 
[82]. Furthermore, a meta-analysis of individual patient data from 3 case-control studies, 
looking at the risk of GI bleeding with individual NSAIDs, included paracetamol as a 
comparator and found no increased risk of GI bleeding with increasing daily doses of 
paracetamol [83]. 
 
However, recent epidemiological studies have identified a potential increased risk of upper 
GI bleeding with doses of paracetamol   ≥2-3g/d. In 2001, a case-control study was 
conducted using the UK’s General Practice Research Database (GPRD) [84]. Adults aged 40-
79 with no history of prior GI disease or alcohol misuse (n=13,605) were followed up 
between 1993 and 1998. Incidence of upper GI complications was documented, as was 
prescription of paracetamol and potentially confounding medications. Compared with 
nonusers of paracetamol, users of ≤2g/d did not have a significant increase in GI 
complications. However, use of >2g/d had an adjusted relative risk (RR; 95% CI) of 3.6 (2.6 – 
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5.1). When this analysis was confined to those patients with no prior NSAID prescription or 
antecedents of GI disorders (e.g. dyspepsia), the adjusted RR was 5.7 (2.0 – 16.4). When 
combined with NSAID, the risk increased to 13.2 (9.2 – 18.9), indicating a substantial 
interaction. It is important to recognise the potential influence of channelling bias in this 
instance (NSAIDS are not prescribed to those at risk of upper GI bleeding unless necessary, 
so high-risk patients may be disproportionately prescribed paracetamol). The authors tried 
to compensate for this by excluding a history of Mallory-Weiss tear, cancer, oesophageal 
varices, coagulopathy or alcohol-related disease, and adjusting the relative risk for age, 
smoking, upper GI risk factors and concomitant medications, but this (they admitted) cannot 
exclude all bias. Additionally, the study was of prescriptions, not ‘real-world’ use. The 
authors had no data on over-the-counter (OTC) use of paracetamol by patients, and the 
daily dosage was calculated from prescription frequencies; both of which have the potential 
to confound the results (though would not explain the apparent dose-response relationship 
found). The same group later published a follow-up examination of the link between GI 
complications and paracetamol in the GPRD [85], and found a pooled RR of 1.3 (1.1 – 1.5). 
Furthermore, in users of ≥2g/d, the RR was 3.6 (2.6 – 5.1). They did not detect evidence of 
heterogeneity or publication bias.  
 
In 2008, a study of elderly patients in Quebec examined the relation of NSAIDs paracetamol 
≤3g/d, paracetamol >3g/d, and proton pump inhibitors (PPI) [86]. Using paracetamol ≤3g/d 
as the reference population, they found hazard ratios (HR) for GI-related hospitalisation of 
1.2 (95% confidence interval [95% CI] 1.03 – 1.40) for paracetamol >3g/d, 1.63 (95% CI 1.44 
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– 1.85) for NSAID, and 2.55 (95% CI 1.98 – 3.28) for combined usage. With the use of a PPI 
the hazards became nonsignificant except in the combined usage group (Hazard Ratio 2.15 
[95% CI 1.35 – 3.40]). These data would suggest that elderly patients taking paracetamol 
with or without concomitant NSAID are at risk of GI-related hospitalisation. The authors 
hypothesise that the additional, weak, nonspecific COX inhibition from paracetamol could 
have an additive effect to that of NSAIDs, creating an increased risk of gastric mucosal injury 
when used together.  
 
Early RCTs in this area appeared to give reassuring results: One crossover study examining 
the effects of 7 days of paracetamol, ketoprofen or placebo on endoscopic appearances 
found no acute effects of paracetamol on the GI mucosa [87]. However, more recent RCTs 
have been less reassuring. In 2011, Doherty et al. examined the effects of paracetamol 
(3g/d), ibuprofen (1200mg/d) or a combination of the two (ibuprofen 600mg / paracetamol 
1.5g daily, or twice this dosage) for chronic knee pain in a parallel-group RCT of 892 patients 
[79].  Though the study was powered to detect differences in analgesic effect (a 5.5 point 
reduction in the WOMAC pain scale), they also collected data on adverse events. After 13 
weeks, they examined the proportion of the groups that had a decrease in haemoglobin of 
≥1g/dl. This was 19.6% in the ibuprofen group, 20.3% for paracetamol, 24.1% for the low-
dose combination and 38.4% for the high-dose combination, which was significantly 
different to the other three groups. As there was also a small but significant drop in platelet 
count, and an increase in mean cell volume, the authors suggested that the haemoglobin 
decrease was likely due to occult GI blood loss. They concluded that paracetamol 3g/d and 
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ibuprofen 1200mg/d were associated with similar amounts of occult blood loss, and that 
there was an additive effect in the higher-dose combination. More recently, in 2016, the 
authors of the PERFORM trial examined the effects of paracetamol and ibuprofen on 
cardiovascular effects and bleeding using a nested case-control study within their cohort of 
19,120 participants with recent ischaemic stroke [88]. A total of 800 cases were paired with 
1600 controls, and incidence of bleeding (in general, but including intracerebral 
haemorrhage or intraocular bleed) was recorded. They found that use of ≥3g/d was 
associated with bleeding events (OR 3.72 [95% CI 1.58 – 8.75]). Dosages of ≤3g/d were not 
associated with significant risk, but the trend test was significant (p=0.02), indicating a dose-
response relationship.  
 
Based on these data, it seems that when taken regularly in dosages of >2-3g/d (i.e. at daily 
doses normally seen in chronic use) there is a significant risk of GI bleeding with 
paracetamol. The dose-response relationship seen in some of the studies would indicate 
that something in the mechanism of action of paracetamol can cause GI bleeding as an 
adverse effect, and that this effect is additive when combined with NSAIDs.  
 
Hepatotoxicity 
Over the past few decades there have been several case reports and small studies implying 
a connection between the ingestion of therapeutic dosages of paracetamol and liver injury 
[89]. It has been known for many years that therapeutic paracetamol use (≤4g/d) has been 
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associated with subclinical rises in liver injury markers [77]. However, transient rises in 
alanine aminotransferase (ALT) can be secondary to many factors, such as exercise, vitamin 
intake, congestive heart failure, diabetes and medications such as aspirin, heparins and 
statins [90, 91]. Whether such an enzyme rise results in clinically-significant liver injury is 
less clear. Heard et al. looked at this issue with healthy volunteers in an RCT of long-term 
paracetamol ingestion (dose 4g/d). They found that ~50% of the paracetamol group 
experienced no ALT rise, ~25% had a transient rise gone by day 16, and ~25% had ALT 
normalise by day 40 [92]. These findings agree with Dart and Bailey’s review of >40,000 
patients’ worth of observational data showing a low incidence of transaminitis (0.4-1.0%) 
and no progression to hepatotoxicity [93].  
 
Of those case reports of liver injury in patients taking therapeutic doses, additional factors 
such as alcohol abuse, nutritional deficiency or concurrent febrile illness are usually present 
[94]. As the toxic metabolite of paracetamol NAPQI is produced via Cytochrome P450 
metabolism (predominantly the CYP2E1 isoenzyme), clinicians have hypothesised that 
induction of these enzymes through alcohol misuse might predispose patients to liver injury. 
This appeared to be supported by animal studies showing that CYP2E1 was induced by 
ethanol in rodents, and that levels of NAPQI and hepatotoxicity were increased when 
paracetamol was administered [89]. However, researchers have failed to replicate this 
finding in humans, and have found evidence of the opposite: CYP2E1 appears to increase 
only modestly with short-term alcohol use, reversing soon after abstinence [89], and one 
examination of cirrhotic livers found them to have 59% less CYP2E1 than control samples 
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[95]. In addition, NAPQI levels are not increased in chronic alcoholics taking paracetamol 
and, although the drug’s half-life is prolonged in chronic liver disease, this does not 
significantly affect metabolism or lead to NAPQI accumulation/hepatotoxicity [89, 96]. 
Similarly, taking cytochrome P450 enzyme-inducing medication (such as rifampicin and P450 
enzyme-inducing anticonvulsants) does not seem to lead to an increased production of 
NAPQI when paracetamol is taken at therapeutic doses [97]. This has led some researchers 
to hypothesise that glutathione depletion may be the causal factor in those few cases where 
therapeutic-dosage paracetamol has resulted in liver injury [94]. Glutathione must be >70% 
deplete before NAPQI starts to accumulate, but in a starvation state (such as that seen in 
some alcoholics) this could occur. Indeed, it is known that chronic alcohol misuse is 
associated with glutathione deficiency [98]. Despite these concerns, due to its lack of a 
direct effect on coagulation (though there is evidence that a dose of 4g/day taken for two 
weeks raises the INR of patients taking warfarin by ~0.8 [99]) and (apparent) GI safety 
profile, paracetamol remains the first-line analgesic of choice for patient with chronic liver 
disease [100]. There does not seem to be evidence for therapeutic paracetamol treatment 
causing hepatotoxicity, either in healthy individuals or chronic liver disease patients, with 
the exception of those in a poor nutritional state [101, 102]. 
 
Hepatotoxicity in children 
Children metabolise paracetamol differently from adults [103], and there is some concern 
that children may also suffer as a result of ingestion of therapeutic dosages of paracetamol. 
This prompted Lavonas et al. to perform a systematic review in 2010, examining 62 studies 
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and >32,000 children receiving therapeutic-dosage paracetamol (≤75mg/kg/d, up to a 
maximum of 4g/d) for an average of 3-5 days [90]. The range of settings (inpatient, 
outpatient, primary care, developed & developing world) and indications for paracetamol 
(infective illness, postoperative pain) was comprehensive. In their analysis, no child showed 
symptoms of liver disease, and only 10 showed any hepatic adverse events at all (incidence 
0.031%, 95% CI 0.015 – 0.057%). They concluded that short-term, therapeutic dose 
paracetamol is not associated with significant hepatotoxicity.  
 
Renal 
Acute kidney injury (AKI) is said to occur in 1-2% of patients with paracetamol overdose [104] 
and most commonly occurs in the setting of severe paracetamol-induced hepatotoxicity 
[105]. Renal biopsy, while not often performed, shows evidence of acute tubular necrosis, 
particularly of the proximal tubule [104]. While the explanation for hepatotoxicity is well 
known [18], the causes of renal toxicity are less clear: possible reasons include the local 
generation of NAPQI or other toxic metabolites from paracetamol by cytochrome P450 or 
COX enzymes [106]. Administration of N-acetylcysteine has no effect on peak creatinine 
concentration, suggesting that depletion of glutathione stores is not the sole cause of renal 
toxicity [107, 108].  The clinical outcome from paracetamol-induced nephrotoxicity in the 
absence of concomitant liver failure is good, with only 1% of patient needing temporising 
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Analgesic nephropathy is characterised by interstitial nephritis and progressive reduction in 
renal size due to repeated episodes of papillary necrosis. The association between the 
analgesic phenacetin and nephropathy was first described in 1953 [109] and by the 1970s 
analgesic nephropathy was reported to be responsible for at least 10-20% of cases of chronic 
renal failure in the UK and Australia [109]. Despite phenacetin’s withdrawal from sale in the 
1980s, analgesic nephropathy has not been eradicated, suggesting other agents may also be 
responsible [110, 111].  As the major active metabolite of phenacetin is paracetamol [112], 
some questioned whether chronic paracetamol use might also cause chronic kidney disease. 
In 1994, Perneger et al. studied 716 subjects with end-stage renal disease (ESRD) and found 
that ESRD was associated with an increase of paracetamol use in a dose-dependent fashion, 
with ~10% of the overall incidence of ESRD attributable to paracetamol use [113]. The study 
unfortunately failed to adjust for possible previous use of phenacetin and NSAIDs, bringing its 
results into question.  A large review in 2000, requested by the regulatory authorities of 
Germany, Switzerland and Austria, examined all published data on non-phenacetin analgesic 
nephropathy [114]. Overall, its findings were that there was insufficient evidence to claim 
non-phenacetin-containing analgesics were causally associated with nephropathy, suggesting 
further research was required [114]. 
Pregnancy 
Paracetamol is administered to pregnant women as an anti-pyretic agent and for the 
management of mild to moderate pain. The presumed safety of this agent has resulted in 
paracetamol becoming one of the most common prescriptions in pregnancy: ~50-60% of 
pregnant women in North and Western Europe self-report using this medication [115]. Its 
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popularity is mainly due to the recommendation of paracetamol over other analgesics, with 
NSAIDs having a less favourable risk profile in pregnant women, and use of aspirin limited 
due to concerns over its effect on the fetus [116, 117].  
 
In recent years, the safety of paracetamol in pregnancy has come under increasing scrutiny. 
Paracetamol and its metabolites cross the placenta [118] and undergo different PK/PD 
processes in neonates than in adults: an immature glucuronide conjugation system makes 
the sulfation pathway the major route of metabolism in neonates [119]. Paracetamol has 
been postulated to cause a diverse range of embryo-fetal and neonatal adverse effects, 
dependent on dose, duration of treatment and the trimester of exposure. However, large 
cohort studies have not found an association between maternal paracetamol use in the first 
trimester and either adverse pregnancy outcomes or congenital malformations [120, 121]. 
Nevertheless, there is some evidence of increased risk with paracetamol use in pregnancy 
and neurodevelopmental disorders, respiratory illness and reproductive toxicity. 
 
Neurodevelopmental  
The association between paracetamol exposure in utero and the risk of long-term 
neurological disorders has been the focus of several controversial pharmaco-
epidemiological studies. Brandlistuen et al. (2013) suggested maternal paracetamol use for 
>28 days during pregnancy was associated with problems in gross motor development, 
communication, externalising and internalising behaviour, and higher activity levels, when 
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compared to controls [122]. These data were obtained from a Norwegian sibling-controlled 
study (n=2919) and based on parental reports of child behaviour at 18 and 36 months. 
Notably, the group also reviewed ibuprofen exposure, to control for possible confounders 
arising from paracetamol indication, and concluded ibuprofen exposure was not associated 
with adverse neurodevelopmental outcomes. There was no relation between trimester of 
exposure to paracetamol and any of the above outcomes.  
 
Maternal paracetamol use was later linked to a neurodevelopmental clinical outcome in the 
Danish National Cohort Study. Liew et al. suggested that maternal paracetamol use during 
pregnancy was associated with a higher risk of receiving a hospital diagnosis of hyperkinetic 
disorder (HR 1.37, 95% CI, 1.19-1.59), use of ADHD medications (HR 1.29, 95% CI 1.15-1.44), 
or having ADHD-like behaviors at age 7 years (HR 1.13, 95% CI, 1.01-1.27) [123]. The 
strengths of this flagship study lie in its large sample size (n=64,322) and adjustment for a 
large number of potential confounders. Notably, these associations were stronger with 
increased frequency of paracetamol use and were not confounded by maternal 
inflammation and infection during pregnancy. Using hospital outcome coding data in the 
same patient cohort, the group later identified an association between prenatal 
paracetamol use and an increased risk of autistic spectrum disorder (ASD) accompanied by 
hyperkinetic symptoms (HR 1.51, 95% CI 1.19–1.92), but not with other ASD cases [124]; 
other studies have suggested an association with ASD symptoms in male offspring only, with 
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The mechanism by which paracetamol and its metabolites may impact on neurological 
development is poorly understood. Animal studies have reported behavioural and cognitive 
changes in mice given paracetamol during neonatal brain development, specifically 
locomotor activity and attainment of spatial learning [126]. Levels of brain-derived 
neurotrophic factor (BDNF) in the neonatal brain were affected (significantly increased in 
the frontal, and decreased in the parietal, cortices), postulating this may be the mechanism 
of action. The role of BDNF in development and brain maturation has been extensively 
reviewed elsewhere [127]. 
In conclusion, on the basis of these studies, only weak associations between paracetamol 
exposure and neurodevelopmental issues are identified, and no causal link can be inferred. 
The epidemiological studies that support a link are subject to confounding by unmeasured 
environmental factors, recall bias, diagnostic inaccuracy (most rely on coding data or 
parental recall for their outcomes), and differences in drop-out rates. Notably, few studies 
confirm the effect of duration and timing of paracetamol exposure, details critical in the 
assessment of toxicological risk in pregnancy. 
 
Asthma 
The potential mechanisms by which paracetamol may contribute to the 
development/exacerbation of asthma are detailed earlier. How paracetamol exposure in 
utero could cause asthma is less clear, unless glutathione levels are lowered in the fetus 
sufficient to affect lung development. Some support for maternal intake of paracetamol 
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affecting offspring comes from mouse studies, where adult mice exposed to paracetamol in 
utero underwent an allergic airway challenge [128]. Increased airway infiltration by 
leukocytes (notably eosinophils) was observed, suggesting an increased susceptibility to 
asthma, but this finding has not been consistently reproduced [129]. 
The Avon Longitudinal Study of Parents and Children was one of the first epidemiological 
studies to examine the causal link between paracetamol exposure during pregnancy and 
childhood asthma [130]. Frequent paracetamol use in late pregnancy (20–32 weeks) was 
associated with an increased risk of wheezing in the offspring at 30–42 months (adjusted OR 
2.10, 95% CI 1.30 to 3.41), particularly if wheezing started before 6 months (termed 
‘persistent wheezers’ – OR 2.34, 95% CI 1.24 to 4.40). Two further cohort studies suggested 
paracetamol use during any time of pregnancy was associated with a small increased risk of 
asthma or bronchitis among children at 18 months (RR 1.17, 95% CI 1.13–1.23) and 7 years 
(RR 1.15, 95% CI 1.02–1.29) [131, 132]. Interestingly, maternal pain showed a positive 
association with asthma development without the use of paracetamol [132].  
 
However, maternal infections, including respiratory infections, are already associated with 
an increase in childhood asthma [133, 134]. Paracetamol use may simply be a surrogate for 
these disease states. Notably, maternal paracetamol use for non-infectious disorders 
revealed no increased risk of wheezing in children [135]. Further studies expanded on this 
theme of confounding by paracetamol indication and have highlighted that the increased 
risk of asthma diagnosis in children exposed to paracetamol prenatally (unadjusted OR 1.36, 
95% CI 1.14-1.61) drops significantly (OR 1.26, 95% CI 1.02-1.58) when adjusted for potential 
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confounders [136]. For an in-depth review of paracetamol exposure and asthma in children, 
and the issue of confounding, see elsewhere [63]. Further clarification of this issue will be 
difficult, as RCTs would be both unethical and impractical [55].  
 
Endocrine & Reproductive toxicity 
The incidence of cryptorchidism is reportedly increasing, which is particularly concerning 
given its association with early adulthood disorders such as low sperm count and testicular 
germ cell cancers [137]. When considered together, these conditions represent a testicular 
dysgenesis syndrome, a disorder related to androgen disruption during the fetal 
programming window [138]. Experimental data have shown reduced testicular 
prostaglandin and testosterone production and reduced ano-genital distance (a marker for 
androgen action)  in rats prenatally exposed to paracetamol [139]. Prenatal paracetamol 
exposure likely results in reduction of key steroidogenic enzymes (Cyp11a1, Cyp17a1), 
implicated in the reduced fetal plasma testosterone (45% reduction; P = 0.025) and seminal 
vesicle weight (18% reduction; P = 0.005) [140]. These changes were noted in castrated host 
mice bearing human fetal testis xenografts following exposure to therapeutic doses of 
paracetamol for 7 days. Notably, however, exposure for 1 day had no effect [140]. Another 
recent study has linked reduced germ cell development in human fetal testes and ovary 
xenografts when exposed to paracetamol; this effect was linked to PGE2-mediated 
alterations in epigenetic regulatory genes, indicating that the effect of paracetamol on the 
fetus may affect the genetics of subsequent generations [141].  
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Several clinical studies associate paracetamol exposure during pregnancy with increased 
occurrence of cryptorchidism, particularly when used in for >2 weeks in the second 
trimester [139, 142, 143]. Few of these studies considered indication for paracetamol use in 
their analyses, and latterly, reanalysis of these data sets showed slightly lower hazard ratios 
for paracetamol exposure during weeks 8–14 among women who did not report an illness 
that would trigger weak analgesic use [144]. This is an interesting paradoxical observation 
given this time frame represents the human fetal programming window, disruption of which 
has previously been linked to reduced male infant ano-genital distance [138, 145]. However, 
we should also note that several large cohort studies have not identified any association 
between paracetamol and cryptorchidism [120, 146-148]. Indeed, the use of paracetamol 
may decrease the risk of selected congenital abnormalities when used for febrile illness 
[147]. 
 
The continuing search for evidence that paracetamol causes harm in pregnancy clearly 
highlights the difficulty in implying causation from pharmaco-epidemiological studies. 
Extrapolation of pre-clinical toxicology data to humans may suggest associations with 
asthma, ADHD and androgen disruption but the small associations seen in clinical cohort 
studies may be explained by various confounders and biases inherent in the study designs. 
Confidently teasing apart these issues would require randomised control trials, which would 
be difficult to perform ethically in pregnant populations. Carefully designed, long-term, 
sibling- and sex-matched cohort studies are more ethically acceptable, and would further 
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our understanding of the risks. Whilst the evidence-base is uncertain, care should be taken 
to avoid raising poorly founded concerns among pregnant women because of the risk of 
switching to other analgesic/ antipyretic drugs with less favourable risk profiles [116]. 
Untreated febrile illness is associated with severe harm to both mother and child, posing a 
far greater risk than that postulated for paracetamol exposure [133, 149-151]. Practical 
advice would be to avoid protracted use of paracetamol for non-febrile illness, a view 
shared by many study authors [140, 152]. 
 
Discussion 
Clearly, there remains considerable uncertainty regarding the chronic adverse effects of 
paracetamol usage. The evidence base in each of the above sections relies mostly on 
observational and cohort studies, and so is prone to inherent biases. The positive 
associations found in these studies are generally weak, and often contradictory. Few RCTs 
have been performed, but, when undertaken, usually give reassuring results. Further studies 
are required in many areas, but RCTs may be difficult to perform, either because they would 
need to be very large to detect the modest increases in risk seen in the observational 
studies, or because of the significant ethical issues of using placebo in patients in pain, as 





This article is protected by copyright. All rights reserved. 
The two areas where the evidence is most convincing are hypertension and gastrointestinal 
bleeding. A small BP rise of 4 mmHg would be clinically important at the population level, 
and the outcome of ongoing RCTs should clarify the reliability of this estimate. This may be 
particularly important in patients with angina or pre-existing hypertension. The fairly 
consistent evidence for GI bleeding associated with paracetamol use, along with its additive 
effect when combined with NSAIDs, may be less well known but similarly important. When 
considering prescribing paracetamol in the chronic setting it would seem wise to consider 
these adverse effects, based on current data, and discuss them with the patient.  
 
Whether paracetamol usage in the chronic setting should be restricted is doubtful, given the 
alternatives are NSAIDs and opioids. Indeed, in patients intolerant of NSAIDs their next 
option would be opioid medication, which come with risks of addiction, drowsiness and fatal 
accidental overdose.  
 
In summary, the average therapeutic effect for chronic pain syndromes is small, but there is 
accumulating evidence of clinically significant adverse effects in chronic use. Despite this, for 
patients who derive clear symptomatic benefit, or only take occasional therapeutic doses, 
the risks are probably very small. For this reason, paracetamol can be seen as the ‘least-
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Conclusion 
This review is designed to provide an objective summary of the evidence-base for chronic 
adverse effects of paracetamol use. We hope that by highlighting the key epidemiological 
studies, RCTs, meta-analyses and reviews we have provided a valuable summary of 
knowledge in this field.  We hope this work will help clinicians and their patients make an 
evidence-based, informed decision regarding their chronic pain management, based on the 
likelihood of clinically-relevant adverse effects.
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Figure 1: Outline of search strategy 
